The purpose of this review is to show current approach to diagnostics of diffuse large B- cell lymphoma on molecular levels, to summarize current first-line treatment options for newly diagnosed diffuse large B- cell lymphoma patients and to introduce new treatment possibilities, which are currently under investigation in clinical trials.